In Florida, Dyadic International announced that the Company has filed a replacement Registration Statement on Form 10-12G with the Securities and Exchange Commission. On November 5, 2018, the Company filed its initial Form 10-12G (File No. 000-55264), which was withdrawn on January 2, 2019 in order to prevent the Initial Form 10 from becoming effective […]
In Florida, Dyadic International, Inc. announced that its Board of Directors has authorized a new stock repurchase program, under which the Company may repurchase up to $5 million of its outstanding common stock. Under this new stock repurchase program, Dyadic may repurchase shares in accordance with all applicable securities laws and regulations, including Rule 10b-18 […]
Every July in American baseball a quiet shake-up occurs around what’s known as the trade deadline. Right at the trade deadline, players rosters come under the microscope. Are we getting enough home runs from the right fielder? Could we find a cheaper options for first base? At that time, some teams are in the hunt […]
In Florida, Dyadic International announced the closing of the previously announced sale of substantially all of the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash. As previously announced, following the closing, Dyadic intends to focus exclusively on its biopharmaceutical business. In connection with the closing of the […]
In Florida, Dyadic reported net Income for Q3 2015 of $1.3 million compared to a net loss of $1.2 million, or ($0.04) per basic and diluted share, for the same period a year ago. At September 30, 2015, cash and cash equivalents were approximately $6.3 million compared to $2.5 million at December 31, 2014. On […]
In Delaware, DuPont Industrial Biosciences has signed an agreement to purchase enzyme and technology assets from Dyadic International Inc., including Dyadic’s C1 platform, a fungal expression technology for producing enzymes. The transaction will further extend the world-leading biotechnology capabilities of DuPont’s Industrial Biosciences business. Under the terms of the agreement, DuPont will pay $75 million […]
As Dyadic cashes out of industrial biotech and retains a C1 license for pharma, DSM and Syngenta also announce a partnership. Companies are girding their loins for the long haul. The Digest takes a look, In Florida, DuPont Industrial Biosciences will acquire substantially all of the enzyme and technology assets Dyadic’s Industrial Technology business for $75 […]
In Florida, Dyadic received the test results from the mice trials in a research program with Sanofi Pasteur indicating that the C1-produced antigen generated an equal, or better, immune response in mice than the industry standard antigen. At the same time, Dyadic joined the EU-funded Zoonoses Anticipation and Preparedness Initiative, a/k/a/ ZAPI, which aims to develop […]
In Florida, Dyadic International has reached a settlement with one of the three remaining defendant law firms in its ongoing professional liability litigation. The Agreement with Defendants Moscowitz & Moscowitz, PA, Norman Moscowitz and Jane Moscowitz was fully executed on July 31, 2015. Payment of the confidential settlement amount to the Company by the Moscowitz […]
In Florida, Dyadic announced details regarding 2G BIOPIC, a new advanced biofuels project funded by the European Commission’s Horizon 2020 program. In the 2G BIOPIC project, Dyadic’s subsidiary Dyadic Netherlands B.V. will work in collaboration with Compagnie Industrielle de Matiere Vegetale (“CIMV”) and five other industry partners to develop, construct and operate a large demonstration-scale facility that […]
